NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 193 filers reported holding NEKTAR THERAPEUTICS in Q1 2023. The put-call ratio across all filers is 0.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $137 | +315.2% | 229,841 | +300.9% | 0.00% | – |
| Q2 2023 | $33 | -69.4% | 57,332 | -62.5% | 0.00% | – |
| Q1 2023 | $108 | -71.0% | 152,754 | -6.8% | 0.00% | – |
| Q4 2022 | $372 | -99.9% | 163,900 | +13.5% | 0.00% | -100.0% |
| Q3 2022 | $463,000 | -52.3% | 144,454 | -43.5% | 0.00% | 0.0% |
| Q2 2022 | $971,000 | -6.2% | 255,536 | +33.1% | 0.00% | 0.0% |
| Q1 2022 | $1,035,000 | -55.5% | 191,969 | +11.5% | 0.00% | – |
| Q4 2021 | $2,326,000 | -7.4% | 172,106 | +23.1% | 0.00% | -100.0% |
| Q3 2021 | $2,512,000 | -30.0% | 139,814 | -33.2% | 0.00% | -50.0% |
| Q2 2021 | $3,591,000 | +926.0% | 209,363 | +1094.5% | 0.00% | – |
| Q1 2021 | $350,000 | -77.4% | 17,527 | -80.8% | 0.00% | – |
| Q4 2020 | $1,547,000 | -61.5% | 91,054 | -62.4% | 0.00% | -100.0% |
| Q3 2020 | $4,019,000 | -39.2% | 242,210 | -15.1% | 0.00% | -60.0% |
| Q2 2020 | $6,605,000 | -34.3% | 285,205 | -49.3% | 0.01% | -37.5% |
| Q1 2020 | $10,046,000 | +2.1% | 562,875 | +23.5% | 0.01% | +33.3% |
| Q4 2019 | $9,835,000 | -22.6% | 455,660 | -34.7% | 0.01% | -33.3% |
| Q3 2019 | $12,714,000 | -30.0% | 698,094 | +36.8% | 0.01% | -18.2% |
| Q2 2019 | $18,159,000 | +34.5% | 510,417 | +27.0% | 0.01% | +22.2% |
| Q1 2019 | $13,506,000 | +4.5% | 401,877 | +2.2% | 0.01% | -10.0% |
| Q4 2018 | $12,928,000 | -65.7% | 393,356 | -36.3% | 0.01% | -61.5% |
| Q3 2018 | $37,644,000 | +0.4% | 617,556 | -19.5% | 0.03% | -18.8% |
| Q2 2018 | $37,483,000 | -4.0% | 767,603 | +108.9% | 0.03% | +6.7% |
| Q1 2018 | $39,055,000 | +23.6% | 367,533 | -30.5% | 0.03% | +20.0% |
| Q4 2017 | $31,593,000 | +254.3% | 529,012 | +42.4% | 0.02% | +150.0% |
| Q3 2017 | $8,917,000 | +56.7% | 371,532 | +27.6% | 0.01% | +66.7% |
| Q2 2017 | $5,691,000 | -50.7% | 291,123 | -40.8% | 0.01% | -50.0% |
| Q1 2017 | $11,541,000 | +784.4% | 491,701 | +362.8% | 0.01% | +1100.0% |
| Q4 2016 | $1,305,000 | +191.9% | 106,251 | +307.5% | 0.00% | – |
| Q3 2016 | $447,000 | +21.8% | 26,074 | +0.6% | 0.00% | – |
| Q2 2016 | $367,000 | +364.6% | 25,924 | +324.1% | 0.00% | – |
| Q1 2016 | $79,000 | -93.0% | 6,113 | -91.3% | 0.00% | -100.0% |
| Q4 2015 | $1,129,000 | +60.1% | 70,510 | +0.0% | 0.00% | 0.0% |
| Q3 2015 | $705,000 | -18.8% | 70,508 | -2.5% | 0.00% | – |
| Q2 2015 | $868,000 | -72.9% | 72,286 | -75.2% | 0.00% | -100.0% |
| Q1 2015 | $3,206,000 | +58.2% | 291,489 | +115.9% | 0.00% | +300.0% |
| Q4 2014 | $2,027,000 | +97.6% | 135,035 | +58.0% | 0.00% | – |
| Q3 2014 | $1,026,000 | -82.2% | 85,485 | -82.2% | 0.00% | -100.0% |
| Q2 2014 | $5,752,000 | +152.6% | 479,284 | +152.7% | 0.01% | +200.0% |
| Q1 2014 | $2,277,000 | +260.3% | 189,689 | +229.8% | 0.00% | – |
| Q4 2013 | $632,000 | -91.6% | 57,519 | -92.4% | 0.00% | -100.0% |
| Q3 2013 | $7,557,000 | +138.1% | 755,770 | +175.0% | 0.01% | +200.0% |
| Q2 2013 | $3,174,000 | – | 274,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rhenman & Partners Asset Management AB | 508,000 | $6,132,000 | 1.80% |
| Bodri Capital Management, LLC | 250,000 | $3,018,000 | 1.46% |
| Granahan Investment Management | 3,442,980 | $41,557,000 | 1.28% |
| TIRSCHWELL & LOEWY INC | 603,441 | $7,284,000 | 1.22% |
| NEA Management Company, LLC | 1,825,600 | $22,035,000 | 1.12% |
| Cormorant Asset Management, LP | 450,000 | $5,432,000 | 1.12% |
| HARVEY CAPITAL MANAGEMENT INC | 221,750 | $2,676,000 | 1.05% |
| Cheyne Capital Management (UK) LLP | 229,577 | $2,772,000 | 0.99% |
| Artal Group S.A. | 1,650,000 | $19,916,000 | 0.73% |
| FIC CAPITAL INC | 147,293 | $1,778,000 | 0.71% |